



Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 – HITAC Update

Shelly Spiro, Co-Chair

Hans Buitendijk, Co-Chair

August 17, 2023



Agenda

- Task Force Charge
- Task Force Membership
- Task Force Progress
 - Major Themes Discussed for Task 1, and Task 2a and 2b
 - Emerging Overarching Themes



Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Charge

Overarching charge: Identify recommendations to support interoperability between pharmacy constituents, and the exchange of information necessary for medication management, patient safety and consumer engagement.

Recommendations Due: November 9, 2023

Specific charge:

1. Public Health, Emergency Use Authorizations, and Prescribing Authorities

Short-term

- a. Identify critical standards and data needs for pharmacists and interested parties to participate in emergency use interventions.
- b. Are there actions ONC can take to enable data exchange in support of public health emergency use cases? For example, Test to Treat and COVID-19 treatment prescribing?

Long-term

- a. Recommendations to better integrate pharmacy systems and data for public health surveillance, reporting and public health interventions.



Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Charge (Continued)

Specific charge:

2. Identify opportunities and recommendations to improve interoperability between pharmacy constituents (prescribers, pharmacists, pharmacy benefit managers, dispensers, payers, intermediaries, PDMPs, public health agencies, HIEs, third party service providers, consumers, etc.) for pharmacy-based clinical services and care coordination.
 - a. How can ONC help facilitate adoption and use of standards to support data exchange for pharmacy-based clinical services?
 - b. Which priority pharmacy-based clinical use cases should ONC focus on in the short-term and long-term?
 - c. What technology gaps exist for pharmacists to participate in value-based care?
 - d. What can ONC do to address drug inventory transparency for prescribers and consumers?
3. Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.
 - a. What standards gaps exist for the prescribing and management of:
 - i. specialty medications
 - ii. digital therapeutics
 - iii. gene therapies
4. Identify policy and technology needs and considerations for direct-to-consumer medication services.

Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Roster



Name	Organization	Name	Organization
Hans Buitendijk* (Co-Chair)	Oracle Health	Shelly Spiro (Co-Chair)	Pharmacy HIT Collaborative
Pooja Babbrah	Point-of-Care Partners	Deven McGraw*	Invitae Corporation
Chris Blackley	Prescriptive	Ketan Mehta	Micro Merchant Systems
Shila Blend*	North Dakota Health Information Network	Justin Neal	Noble Health Services
David Butler	Curatro, LLC	Eliei Oliveira*	Dell Medical School, University of Texas at Austin
Steven Eichner*	Texas Department of State Health Services	Naresh Sundar Rajan*	CyncHealth
Rajesh Godavarthi*	MCG Health, part of the Hearst Health network	Scott Robertson	Bear Health Tech Consulting
Adi V. Gundlapalli**	Center for Disease Control and Prevention	Alexis Snyder*	Individual
Jim Jirjis*	HCA Healthcare	Fillipe Southerland*	Yardi Systems, Inc.
Summerpal Kahlon	Rocket Health Care	Christian Tadrus	Community Pharmacy Owner
Steven Lane*	Health Gorilla	Sheryl Turney*	Elevance Health
Meg Marshall**	Department of Veterans Health Affairs	Afton Wagner	Walgreens
Anna McCollister*	Individual		



Task Force Progress

Shelly Spiro, Co-Chair

Hans Buitendijk, Co-Chair

Completed Task Force Topics



<u>Meeting Date</u>	<u>Area of Focus</u>	<u>Invited External SME</u>
June 21	<p data-bbox="443 339 1396 415"><u>TF Topic 1: SHORT-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities</u></p> <p data-bbox="443 472 1345 594">(a) Identify critical standards and data needs for pharmacists and interested parties to participate in emergency use interventions.</p> <p data-bbox="443 651 1370 815">(b) Are there actions ONC can take to enable data exchange in support of public health emergency use cases? For example, Test to Treat and COVID-19 treatment prescribing?</p>	<ul data-bbox="1442 329 1564 362" style="list-style-type: none"> <li data-bbox="1442 329 1564 362">• N/A
June 28	<p data-bbox="443 918 1396 993"><u>TF Topic 1: SHORT-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities</u></p> <p data-bbox="443 1051 1345 1172">(a) Identify critical standards and data needs for pharmacists and interested parties to participate in emergency use interventions.</p> <p data-bbox="443 1229 1370 1392">(b) Are there actions ONC can take to enable data exchange in support of public health emergency use cases? For example, Test to Treat and COVID-19 treatment prescribing?</p>	<ul data-bbox="1442 951 2405 1386" style="list-style-type: none"> <li data-bbox="1442 951 2405 1029">• RDML (retired) Pamela Schweitzer, Assistant Surgeon General and 10th Chief Pharmacist USPHS <li data-bbox="1442 1036 2405 1115">• Lisa Schwartz, Senior Director, Professional Affairs, National Community Pharmacists Association (NCPA) <li data-bbox="1442 1122 2405 1200">• Darren Townzen, Senior Director Health and Wellness Billing and Reconciliation, Walmart <li data-bbox="1442 1208 2405 1286">• Chad Worz, Executive Director and CEO, American Society of Consultant Pharmacists (ASCP) <li data-bbox="1442 1293 2405 1386">• Michael Popovich, CEO and Jason Briscoe, Director of Pharmacy Operations, STC Health

Completed Task Force Topics (Continued)



Meeting Date

Area of Focus

Invited External SME

July 12

TF Topic 1: LONG-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities

**(a) Recommendations to better integrate pharmacy systems and data for public health surveillance, reporting and public health interventions.
Discussion of draft recommendations**

- Tegan K Boehmer, PhD, MPH, CDR, US Public Health Service Acting Chief, Actionable Data Branch (proposed), Inform and Disseminate Division (proposed), Office of Public Health Data, Surveillance, and Technology

July 19

TF Topic 1: LONG-TERM Public Health, Emergency Use Authorizations, and Prescribing Authorities

**(a) Recommendations to better integrate pharmacy systems and data for public health surveillance, reporting and public health interventions.
Discussion of draft recommendations**

- Laura Conn, MPH, Lead, Electronic Case Reporting (eCR), Public Health Data Transmission Branch (proposed), Detect and Monitor Division (proposed), Office of Public Health Data, Surveillance and Technology, CDC
- Lynn Gibbs Scharf, MPH, Chief, Informatics and Data Analytics Branch, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC
- Agha (Nabeel) Khan, MD, MPH, MBA, Senior Advisor for Informatics, Office of Informatics, National Center for Immunization & Respiratory Diseases, CDC



Completed Task Force Topics (Continued)

Meeting Date

Area of Focus

Invited External SME

July 26

TF Topic 2: Identify opportunities and recommendations to improve interoperability between pharmacy constituents for pharmacy-based clinical services and care coordination

(a) How can ONC help facilitate adoption and use of standards to support data exchange for pharmacy-based clinical services?

- Kim Boyd, President, Boyd Consulting Group, LLC
- Stephen Mullinex, BS Pharm., R.Ph., Senior Vice President, Public Policy & Industry Relations, NCPDP
- Richard Sage, Executive Vice President, Innovation & Standards Development, NCPDP
- Josh Howland, Pharm.D., MBA, SVP Clinical Strategy & Product, RedSail Technologies

August 9

TF Topic 2: Identify opportunities and recommendations to improve interoperability between pharmacy constituents for pharmacy-based clinical services and care coordination

(b) Which priority pharmacy-based clinical use cases should ONC focus on in the short-term and long-term?

- Jake Galdo, PharmD, MBA, BCPS, BCGP Managing Network Facilitator, CPESN Health Equity and CEO, Seguridad



Completed Task Force Topics (Continued)

Meeting Date

Area of Focus

Invited External SME

August 16

TF Topic 2: Identify opportunities and recommendations to improve interoperability between pharmacy constituents for pharmacy-based clinical services and care coordination

(c) What technology gaps exist for pharmacists to participate in value-based care?

- N/A



Upcoming Task Force Topics

Meeting Date

Area of Focus

August 23

TF Topic 2: Identify opportunities and recommendations to improve interoperability between pharmacy constituents for pharmacy-based clinical services and care coordination

(d) What can ONC do to address drug inventory transparency for prescribers and consumers?

August 30

TF Topic 3: Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.

**(a) What standards gaps exist for the prescribing and management of:
i. specialty medications**

September 13

TF Topic 3: Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.

**(a) What standards gaps exist for the prescribing and management of:
ii: digital therapeutics**



Upcoming Task Force Topics (Continued)

Meeting Date

Area of Focus

September 20

TF Topic 3: Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.

**(a) What standards gaps exist for the prescribing and management of:
iii: gene therapies**

September 27

TF Topic 3: Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.

**(a) What standards gaps exist for the prescribing and management of:
iv: any other emerging therapeutic areas the TF has identified**

October 4

TF Topic 4: Identify policy and technology needs and considerations for direct-to-consumer medication services.

October 11

TF Topic 4: Identify policy and technology needs and considerations for direct-to-consumer medication services.



Upcoming Task Force Topics (Continued)

Meeting Date**Area of Focus****October 18**

Revise and finalize Task Force recommendations

October 25

Revise and finalize Task Force recommendations

November 1

Revise and finalize Task Force recommendations

November 9

Final recommendations delivered to HITAC

Major Themes Discussed for Tasks 1 and 2

Task 1: Public Health, Emergency Use Authorizations, and Prescribing Authorities

- Standards & Data Exchange
- Pharmacist-Physician Collaboration and Clinical Data Sharing
- Pharmacist-Public Health Collaboration and Data Sharing
- Pharmacist Data Capture
- Pharmacist-Special Settings/Populations/Long Term Care Collaboration and Data Sharing
- Information Sharing/Blocking
- Jurisdictional Variations of Standards and Rules
- Resources/Funding
- Privacy and Consent

Task 2 (a, b): Identify opportunities and recommendations to improve interoperability between pharmacy constituents for pharmacy-based clinical services and care coordination.

- Data Queries
- Push Messaging
- Network-Based Exchange
- Patient Matching
- USCDI Alignment
- Use Cases – Foundational Capabilities, Short-Term, Long-Term, Priority
- First Steps





Emerging Overarching Themes

- How to enable use of existing technologies, standards, and networks? What are barriers to adoption?
- Education on technologies, authorities, privacy, etc.
- Contractual arrangements
- Funding and incentives
- Role of USCDI, certification and need of use case and setting based focus



Discussion